Topic

Chris Spivey is the editorial director of 

Articles

If the Alliance for mRNA Medicines (AMM) tested the waters in June 2023 at the BIO Conference in Boston, then they engaged in a full-fledged triathlon in September, in the heat and humidity of Washington, DC.

Washington, DC Houses mRNA Leadership

mRNA may be a modality whose chief advances are yet to come.  

New Magic from mRNA

Grant Playter is the Assistant Editor for 

If we view a change opposite of one’s interest as antithetical to innovation, we risk losing sight of our ultimate goal.

Innovation Idolatry

Vaccine nationalism strengthens viruses and poses deadly risks for all involved.

Vaccine Nationalism Escalating Risk

Feliza Mirasol is the science editor for 

INTERPHEX was back in full swing with Keynote sessions highlighting cutting-edge technologies that are setting the stage for the bio/pharma industry’s future.

Springing Forward!

What can we take away from Pfizer's acquisition of Seagen?

Zauberkugel: Pfizer’s Seagen Acquisition

This new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns. 

The Commercial Message mRNA Products Send

Coverage of COVID-19 vaccines was surprisingly displaced by this year’s astounding oncology and iconoclastic gene therapy “cures.”

Pedestrians as Priority

mRNA may not be a train we necessarily all need to get onboard immediately, but we should know where the central train station is located, and what it connects us to.

mRNA Hauptbahnhof

Content is king in publishing, but interpretation is imperator.

From the Editor